These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 15121297)

  • 1. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice.
    Basso B; Cervetta L; Moretti E; Carlier Y; Truyens C
    Vaccine; 2004 May; 22(15-16):1868-72. PubMed ID: 15121297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL; Antúnez MI; Abrami AA
    Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
    Basso B; Marini V
    Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of cytokines in resistance and pathology in Trypanosoma cruzi infection].
    Laucella SA; Rottenberg ME; de Titto EH
    Rev Argent Microbiol; 1996; 28(2):99-109. PubMed ID: 8768488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanosoma cruzi: Tc52 released protein-induced increased expression of nitric oxide synthase and nitric oxide production by macrophages.
    Fernandez-Gomez R; Esteban S; Gomez-Corvera R; Zoulika K; Ouaissi A
    J Immunol; 1998 Apr; 160(7):3471-9. PubMed ID: 9531308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of nitric oxide (NO) and TNF-alpha in the oxidative stress associated with anemia in experimental Trypanosoma cruzi infection.
    Malvezi AD; Cecchini R; de Souza F; Tadokoro CE; Rizzo LV; Pinge-Filho P
    FEMS Immunol Med Microbiol; 2004 May; 41(1):69-77. PubMed ID: 15094169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection.
    Abrahamsohn IA; Coffman RL
    Exp Parasitol; 1996 Nov; 84(2):231-44. PubMed ID: 8932773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental Chagas disease. Innate immune response in Balb/c mice previously vaccinated with Trypanosoma rangeli. I. The macrophage shows immunological memory: Reality or fiction?
    Basso B; Marini V
    Immunobiology; 2014 Apr; 219(4):275-84. PubMed ID: 24321621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi.
    Hoft DF; Lynch RG; Kirchhoff LV
    J Immunol; 1993 Dec; 151(12):7038-47. PubMed ID: 8258708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production.
    Zhang L; Tarleton RL
    Eur J Immunol; 1996 Jan; 26(1):102-9. PubMed ID: 8566051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of Trypanosoma rangeli against infections with a highly virulent strain of Trypanosoma cruzi.
    Zuñiga C; Palau T; Penin P; Gamallo C; de Diego JA
    Trop Med Int Health; 1997 May; 2(5):482-7. PubMed ID: 9217704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection.
    Miyazaki Y; Hamano S; Wang S; Shimanoe Y; Iwakura Y; Yoshida H
    J Immunol; 2010 Jul; 185(2):1150-7. PubMed ID: 20562260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
    Fontanella GH; De Vusser K; Laroy W; Daurelio L; Nocito AL; Revelli S; Contreras R
    Vaccine; 2008 May; 26(19):2322-34. PubMed ID: 18403070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity against Trypanosoma cruzi provided by oral immunization with Phytomonas serpens: role of nitric oxide.
    Pinge-Filho P; Peron JP; de Moura TR; Menolli RA; Graça VK; Estevão D; Tadokoro CE; Jankevicius JV; Rizzo LV
    Immunol Lett; 2005 Jan; 96(2):283-90. PubMed ID: 15585334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and placental productions of tumor necrosis factor contribute to induce fetal mortality in mice acutely infected with Trypanosoma cruzi.
    Mjihdi A; Truyens C; Detournay O; Carlier Y
    Exp Parasitol; 2004; 107(1-2):58-64. PubMed ID: 15208038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodegeneration and increased production of nitrotyrosine, nitric oxide synthase, IFN-gamma and S100beta protein in the spinal cord of IL-12p40-deficient mice infected with Trypanosoma cruzi.
    Bombeiro AL; D'Império Lima MR; Chadi G; Alvarez JM
    Neuroimmunomodulation; 2010; 17(2):67-78. PubMed ID: 19923851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
    Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
    Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania sp: comparative study with Toxoplasma gondii and Trypanosoma cruzi in their ability to initialize IL-12 and IFN-gamma synthesis.
    Oliveira MA; Santiago HC; Lisboa CR; Ceravollo IP; Trinchieri G; Gazzinelli RT; Vieira LQ
    Exp Parasitol; 2000 Jun; 95(2):96-105. PubMed ID: 10910710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trypanosoma cruzi: protective immunity in mice immunized with paraflagellar rod proteins is associated with a T-helper type 1 response.
    Miller MJ; Wrightsman RA; Manning JE
    Exp Parasitol; 1996 Nov; 84(2):156-67. PubMed ID: 8932765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.
    Hoft DF; Eickhoff CS
    Infect Immun; 2005 Aug; 73(8):4934-40. PubMed ID: 16041007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.